سعر كيترودا 100 مجم / 4 مل فيال 2022

Keytruda (pembrolizumab) 100 mg/4 ml (25 mg/ml) solution for dilution and intravenous infusion, single-dose vial; a PD-1 blocking antibody used across many cancers.

• Melanoma: unresectable or metastatic disease; adjuvant treatment of adults and children 12 years and older with stage IIB, IIC or III melanoma after complete resection.Population: Adults; pediatric 12 years and older (adjuvant)DailyMed (U.S. National Library of Medicine)
• Non-small cell lung cancer in several settings (first-line with or without chemotherapy according to PD-L1 expression and tumour type, previously treated PD-L1-positive disease, resectable and adjuvant settings).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Head and neck squamous cell carcinoma, gastric, esophageal, cervical, hepatocellular, biliary tract, Merkel cell, renal cell, endometrial, cutaneous squamous cell, triple-negative breast and ovarian cancers, and malignant pleural mesothelioma, each in the specific settings (often with chemotherapy or other agents, sometimes requiring PD-L1 testing) defined in the label.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (20% or more) with Keytruda as a single agent: fatigue, musculoskeletal pain, rash, diarrhoea, pyrexia, cough, decreased appetite, pruritus, dyspnoea, constipation, pain, abdominal pain, nausea and hypothyroidism.International label, same product · DailyMed (U.S. National Library of Medicine)
• With chemotherapy or other agents, additional common reactions include nausea, vomiting, alopecia, peripheral neuropathy, mucosal inflammation/stomatitis, neutropenia and anaemia (combination-specific; see label).International label, same product · DailyMed (U.S. National Library of Medicine)
• Postmarketing: exocrine pancreatic insufficiency and sclerosing cholangitis.International label, same product · DailyMed (U.S. National Library of Medicine)

• None (the US label lists no contraindications).International label, same product · DailyMed (U.S. National Library of Medicine)

• Severe and fatal immune-mediated adverse reactions can occur in any organ (e.g. pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions), during or after treatment; withhold or permanently discontinue depending on severity and give systemic corticosteroids as needed.International label, same product · DailyMed (U.S. National Library of Medicine)
• Severe or life-threatening infusion-related reactions, including anaphylaxis, can occur; interrupt or slow the infusion for grade 1-2 reactions and permanently discontinue for grade 3-4.International label, same product · DailyMed (U.S. National Library of Medicine)
• Fatal and serious complications (including graft-versus-host disease and hepatic veno-occlusive disease) can occur with allogeneic hematopoietic stem cell transplantation before or after PD-1/PD-L1 blockade.International label, same product · DailyMed (U.S. National Library of Medicine)

• Based on its mechanism of action, can cause fetal harm; no human data. The PD-1/PD-L1 pathway maintains maternal immune tolerance to the fetus, and blockade in animal models increased fetal loss; human IgG4 crosses the placenta.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on pembrolizumab in human milk; maternal IgG is present in milk. Advise not to breastfeed during treatment and for 4 months after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Pembrolizumab: Binds the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour response.